U.S. flag

An official website of the United States government

NM_000642.3(AGL):c.2654A>G (p.Asp885Gly) AND Glycogen storage disease type III

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Aug 26, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000801695.7

Allele description [Variation Report for NM_000642.3(AGL):c.2654A>G (p.Asp885Gly)]

NM_000642.3(AGL):c.2654A>G (p.Asp885Gly)

Gene:
AGL:amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p21.2
Genomic location:
Preferred name:
NM_000642.3(AGL):c.2654A>G (p.Asp885Gly)
HGVS:
  • NC_000001.11:g.99884676A>G
  • NG_012865.1:g.39593A>G
  • NM_000028.3:c.2654A>G
  • NM_000642.3:c.2654A>GMANE SELECT
  • NM_000643.3:c.2654A>G
  • NM_000644.3:c.2654A>G
  • NM_000646.3:c.2606A>G
  • NM_001425325.1:c.2654A>G
  • NM_001425326.1:c.2654A>G
  • NM_001425327.1:c.2453A>G
  • NM_001425328.1:c.2450A>G
  • NM_001425332.1:c.2276A>G
  • NP_000019.2:p.Asp885Gly
  • NP_000019.2:p.Asp885Gly
  • NP_000633.2:p.Asp885Gly
  • NP_000634.2:p.Asp885Gly
  • NP_000634.2:p.Asp885Gly
  • NP_000635.2:p.Asp885Gly
  • NP_000635.2:p.Asp885Gly
  • NP_000637.2:p.Asp869Gly
  • NP_000637.2:p.Asp869Gly
  • NP_001412254.1:p.Asp885Gly
  • NP_001412255.1:p.Asp885Gly
  • NP_001412256.1:p.Asp818Gly
  • NP_001412257.1:p.Asp817Gly
  • NP_001412261.1:p.Asp759Gly
  • NC_000001.10:g.100350232A>G
  • NM_000028.2:c.2654A>G
  • NM_000642.2:c.2654A>G
  • NM_000643.2:c.2654A>G
  • NM_000644.2:c.2654A>G
  • NM_000646.2:c.2606A>G
Protein change:
D759G
Links:
dbSNP: rs867149434
NCBI 1000 Genomes Browser:
rs867149434
Molecular consequence:
  • NM_000028.3:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000642.3:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000643.3:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000644.3:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000646.3:c.2606A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001425325.1:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001425326.1:c.2654A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001425327.1:c.2453A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001425328.1:c.2450A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001425332.1:c.2276A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Glycogen storage disease type III (GSD3)
Synonyms:
Glycogen storage disease type 3; Forbes disease; Cori disease; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009291; MedGen: C0017922; Orphanet: 366; OMIM: 232400

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000941487Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Uncertain significance
(Aug 26, 2021) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002094497Natera, Inc.
no assertion criteria provided
Uncertain significance
(Mar 18, 2020) 		germlineclinical testing

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000941487.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This sequence change replaces aspartic acid with glycine at codon 885 of the AGL protein (p.Asp885Gly). The aspartic acid residue is weakly conserved and there is a moderate physicochemical difference between aspartic acid and glycine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with AGL-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Natera, Inc., SCV002094497.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 20, 2023